The findings underscore the promise of combinatorial therapy for PAH based on simultaneous targeting of redundant signaling effectors, PDE-5 and ETA, which serve crucial roles in the pathogenesis of PAH. The gene discussed is PDE5A; the disease is pulmonary arterial hypertension.